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June Supplement 201162S Abstracts1 had major amputation (11.1%) and 2 were managed
expectantly. Of the 11 failed PC grafts 4(37%) underwent
major amputation, 4 had new bypasses and 3weremanaged
expectantly.
Conclusions: For patients with inadequate SSGSV,
prosthetic conduit is equivalent to alternative vein sources
in terms of graft patency and limb salvage rates for below-
knee popliteal bypass targets.
Primary
Patency
(%)
Assisted
Primary
Patency
(%)
Secondary
Patency
(%)
Limb
Salvage
(%)
Post-op
Coumadin
Usage (%)
Alternative
Vein
54.9  9.9 68.5  9.5 68.4  9.5 96.4  3.6 27.3
Prosthetic
Conduit
54.6  10.5 56  10.6 68.8  9.1 86.0  6.3 61.5
P-value 0.5 0.2 0.5 0.08 0.001
Author Disclosures: N. R. Barshes: Nothing to disclose;
M. Belkin: Nothing to disclose; J. T. McPhee: Nothing to
disclose; L. L. Nguyen: Nothing to disclose; C. K. Ozaki:
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Arterial Occlusion
Anthony J. Comerota1, David Fineberg2, Richard Shlan-
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Objectives: Plasmin is a direct-acting thrombolytic
that has superior hemostatic safety compared to plasmino-
gen activator in preclinical studies. Here, we report safety
data of plasmin in patients with acute peripheral arterial
occlusion (aPAO).
Methods: This was an open-label, Phase I, dose esca-
lation study of Plasmin (human) TAL-05-00018 (Talecris
Biotherapeutics) in patients with SVS Class I or IIa acute
limb ischemia. Sequential 10-13 patient cohorts received a
single,5-hour intrathrombus dose of Plasmin (25 to 175
mg) by multi-slit catheter using manual pulse-spray injec-
tions followed by continuous infusion. Safety was assessed
with clinical evaluations and monitoring of plasma concen-
trations of fibrinogen and alpha 2-antiplasmin inhibitor at
end of plasmin treatment and on days 1-2, 7, 14 and 30.
Results: Of 83 patients enrolled, 19 (22.9%) had seri-
ous adverse events (SAEs) and 57 (68.7%) had treatment-
emergent (TE) adverse events (AEs). Two patients died
(myocardial infarction, sepsis). Four patients had a major
bleeding event and 14 had minor bleeding events. None of
the SAEs, deaths or bleeding events were reported by
investigators to be Plasmin-related. TEAEs, SAEs, and pleeding events did not increase with Plasmin dose. Mean
ost-treatment fibrinogen nadirs were similar at all plasmin
osages (350 - 440 mg/dL). Furthermore, alpha 2-anti-
lasmin inhibitor and fibrinogen levels were similar in
atients with and without bleeding events.
Conclusions: Plasmin treatment (up to 175 mg) of
atients with aPAO had a favorable safety profile, notably
bsence of treatment-related bleeding and maintenance
f normal fibrinogen concentration. These results sup-
ort further clinical trials of Plasmin for treatment of
PAO.
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S126.
ound Infection after Lower Extremity Bypass In-
reases Hospital Resource Utilization But is Not Asso-
iated with Negative Long-Term Outcomes
effrey Kalish1, Alik Farber1, Andres Schanzer2, Gheorghe
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Objectives: Wound infection (WI) after lower extrem-
ty bypass (LEB) is reported in 5-22% of cases. This com-
lication has been cited by proponents of endovascular
evascularization as a reason to avoid LEB. Although nu-
erous studies have attempted to define predictive risk
actors, long-term effects of WI after LEB have not been
lucidated.
Methods: Using the Vascular Study Group of New
ngland database(2003-2009), we examined 2721 consec-
tive LEB procedures performed by 57 surgeons at aca-
emic and community hospitals. The cohort was stratified
y indication: intermittent claudication (IC) and critical
imb ischemia (CLI). In-hospital WI required documenta-
ion of positive cultures or antibiotic treatment. Primary
ndpoints were ambulation at hospital discharge, 1-year
reedom from major amputation, and 1-year primary
atency.
Results: WI rates were 4.5% (33/734) for IC and 5.5%
109/1987) for CLI. Mean length of stay (LOS) was
ignificantly greater with WI (IC: 3.8 vs 10.1 days,
0.001; CLI: 8.9 vs 13.6 days, p0.001). No signifi-
